Thursday 7 May, 2026
Objectives Tuberculosis (TB) treatment requires prolonged multidrug therapy and exhibits substantial variability in response across patients. Treatment outcomes are determined…
Read moreAbstracts
Design and implementation of a model-optimised paroxetine C-QT study
Thursday 7 May, 2026
Objectives: Paroxetine is an established SSRI with extensive post-marketing safety data over 30 years of use, from which some QT…
Read moreInVitroInVivoCorrelation.jl: A MODULAR JULIA PACKAGE FOR LEVEL A IVIVC
Thursday 7 May, 2026
Introduction: Establishing a robust in vitro-in vivo correlation (IVIVC) remains central to formulation development, clinically relevant dissolution specification setting, and…
Read moreASSESSMENT OF EXPOSURE-RESPONSE CAUSALITY AND HOMOGENEITY VIA PARTITIONED EFFECTS MODELING AND MEDIATION ANALYSIS: A MOXONIDINE CASE STUDY
Thursday 7 May, 2026
Objectives Causality and homogeneity in exposure–response (E-R) analyses can be assessed by the partitioned effects (PE) model, based on an…
Read moreChallenges in Generating a Ground Truth for Method Development in Model-Informed Precision Dosing
Thursday 7 May, 2026
Objectives: In Model-Informed Precision Dosing (MIPD), Bayesian hierarchical models utilize prior knowledge from clinical trials and real world data to…
Read moreAssessing Vancomycin PK Model Performance Across Trough- and AUC-Based Targets in Diverse Patient Populations
Thursday 7 May, 2026
Introduction: Vancomycin remains one of the most extensively studied drugs in population pharmacokinetic (popPK) modeling, with a large number of…
Read morepopPKPD modeling of AZD7798-mediated depletion of CCR9+ T cells in healthy volunteers
Thursday 7 May, 2026
Introduction AZD7798 is a CCR9+ T-cell-depleting monoclonal antibody, recently evaluated in a first-time-in-human study and in development for treatment of…
Read moreJoint modeling of time to positivity (TTP), mycobacterium tuberculosis – molecular bacterial load assay (TB-MBLA), and PATHFAST TB LAM AG test: Quantifying inter-biomarker correlations and drug effects in pulmonary tuberculosis
Thursday 7 May, 2026
Objectives: Tuberculosis (TB) remains a major global health crisis, with an estimated 10.7 million new cases and 1.23 million deaths…
Read moreTOWARDS AN INTEGRATED METABOLISM QUANTITATIVE SYSTEMS PHARMACOLOGY (QSP) MODEL FOR SUPPORTING A PIPELINE OF OBESITY THERAPEUTICS
Thursday 7 May, 2026
Introduction: Incretin-mimetic drugs (IMDs) such as glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP) receptor agonists have revolutionized obesity treatment,…
Read morePharmacometric evaluation of extended interval dosing of IV-administered nivolumab using an established popPK model and sparse trough sampling: REFINE Nivolumab Cohort Interim Pharmacokinetic Analysis
Thursday 7 May, 2026
Introduction: Nivolumab, an immune checkpoint inhibitor (ICI) targeting programmed cell death protein 1 (PD-1), is an ideal candidate for reduced…
Read more